| Literature DB >> 31500570 |
Yi Li1, Xingchun Chen2, Zhijun Zhang3, Lijun Wang4, Junrui Wang5, Ji Zeng6, Junwen Yang7, Binghuai Lu8,9,10.
Abstract
BACKGROUND: Infections by Streptococcus gallolyticus subsp. pasteurianus (SGSP) is often underestimated. Herein, the epidemiological features and resistant characteristics of SGSP in mainland China are characterized to enable a better understanding of its role in clinical infections.Entities:
Keywords: Antibiotic resistance; Intrauterine infection; Streptococcus gallolyticus subsp. pasteurianus
Mesh:
Substances:
Year: 2019 PMID: 31500570 PMCID: PMC6734276 DOI: 10.1186/s12879-019-4413-5
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Demographic and clinical features of 45 isolates of Streptococcus gallolyticus subsp. pasteurianus circulating in mainland China
| Infection types | Gender | Age | Sources | Underlying diseases | Polymicrobial | City/Province | Year of isolation |
|---|---|---|---|---|---|---|---|
| Non-pregnancy-related infections | |||||||
| Abdominal infection | Female | 41–60 | Ascitic fluid | Choledochal cyst | No | Beijing | 2016 |
| Bacteremia(13) | Female(4), Male(9) | ≤20, 21–40(2), 41–60(2), > 60(8) | Blood (13) | Hematuria, aplastic anemia, hematopoietic stem cell transplantation, endometrial carcinoma/colon cancer, fatty liver, cholecystitis, liver cancer, bone pain, abdominal pain, diabetes(3), ALL(2). | Henan(2), Guangxi(5), Hubei(3), Shangdong, Neimenggu(2). | 2014(3), 2015(2),2016(5),2017(3) | |
| Bacteremia/infective endocarditis | Male | 41–60 | Blood | No | Guangxi | 2015 | |
| Biliary infection | Female | > 60 | Bile | Malignant bile duct tumor | No | Beijing | 2013 |
| Intra-abdominal infection | Male | > 60 | Abdominal puncture fluid | No | Hubei | 2014 | |
| Meningitis | Male | ≤20 | CSF | Anemia, pneumonia, congenital heart disease | No | Henan | 2017 |
| Peripancreatic abscess | Female | 41–60 | Peripancreatic drainage | Pancreatic tumor | No | Beijing | 2015 |
| UTI(15) | Female (10), Male (5) | 21–40(2), > 60(13) | Urine (15) | Diabetes (7), hematuria, left renal calculus, hydronephrosis. | Beijing(2), Guangxi(5), Henan(5), Shangdong, Henan (2). | 2011,2012(2), 2013(2), 2014, 2016(3),2017(6) | |
| Pregnancy-related infections | |||||||
| Bacteremia | Female | 21–40 | Blood | Delivery | No | Hubei | 2014 |
| Intrauterine infection(7) | Female (7) | 21–40(7) | Fetal membrane (3), Fetal membrane/placenta (4). | Premature delivery, post-cesarean delivery, delivery (5) | No | Beijing(6), Guangxi | 2011, 2012, 2013, 2014(2), 2015(2) |
| Intrauterine infection/bacteremia(2) | Female (2) | 21–40(2) | Fetal membrane/blood (2) | Post-cesarean delivery | MRSA | Beijing, Guangxi | 2012, 2017 |
| UTI | Female | 21–40 | Urine | No | Guangxi | 2017 | |
F female, M male, CSF cerebrospinal fluid, UTI urinary tract infection, indicating symptomatic patients with bacteriuria, ALL Acute Lymphocytic Leukemia, MRSA methicillin-resistant Staphylococcus aureus; Number in parentheses represents strains, and no number signified only one strain was detected
Fig. 1Geographical locations and numbers of Streptococcus gallolyticus subsp. pasteurianus (SGSP) isolates. The colored provinces represent where SGSP strains were isolated, with the number of isolates shown in brackets
Fig. 2Distribution of the 45 strains of Streptococcus gallolyticus subsp. pasteurianus (SGSP) in different infections
Fig. 3Relationship between infection sources and ages in 34 cases of non-pregnancy-related infections caused by Streptococcus gallolyticus subsp. pasteurianus (SGSP)
Fig. 4Phylogenetic tree constructed by the neighbour-joining method based on the nucleotide sequences of the 16S rRNA genes of 45 clinical Streptococcus gallolyticus subsp. pasteurianus (SGSP) strains and one reference strain AJ297216.1
Antimicrobial susceptibilities and minimum inhibitory concentrations of 45 isolates of Streptococcus gallolyticus subsp. pasteurianus
| Antimicrobials | Breakpoint by CLSI | Susceptibility | MIC | ||||
|---|---|---|---|---|---|---|---|
| S(%) | I(%) | R(%) | MIC50 | MIC90 | Range | ||
| Penicillin | 0.12/0.25–2/4 | 100 | 0 | 0 | 0.125 | 0.125 | < 0.03–0.12 |
| Amoxicillin | 0.25/0.5–4/8 | 100 | 0 | 0 | < 0.25 | < 0.25 | all < 0.25 |
| Cefotaxime | 1/2/4 | 100 | 0 | 0 | < 0.5 | < 0.5 | all < 0.5 |
| Erythromycin | 0.25/0.5/1 | 11.1(5/45) | 0 | 88.9(40/45) | > 4 | > 4 | 0.0625- > 4 |
| Clindamycin | 0.25/0.5/1 | 11.1(5/45) | 0 | 88.9(40/45) | > 4 | > 4 | 0.0625~ > 4 |
| Levofloxacin | 2/4/8 | 73.3(33/45) | 15.6(7/45) | 11.1(5/45) | 2 | 4 | 1~ > 4 |
| Moxifloxacin | 1/2/4 | 88.9(40/45) | 2.2(1/45) | 8.9(4/45) | 0.5 | 1 | ≤0.25~ > 2 |
| Tetracycline | 2/4/8 | 4.4(2/45) | 2.2(1/45) | 93.3(42/45) | > 8 | > 8 | 0.0625~ > 4 |
| Linezolid | 2 | 100 | 0 | 0 | ≤1 | 2 | ≤1~2 |
| Meropenem | 0.5 | 100 | 0 | 0 | ≤0.0625 | ≤0.0625 | ≤0.0625 |
| Vancomycin | 1 | 100 | 0 | 0 | ≤0.25 | ≤0.25 | ≤0.25–1 |
MIC minimum inhibitory concentration, S susceptible, I intermediate, R resistant, MIC50 minimum inhibitory concentration at which 50% of isolates were inhibited, MIC90 minimum inhibitory concentration at which 90% of isolates were inhibited, MIC range range of minimum inhibitory concentration
Erythromycin and tetracycline resistance phenotype and genotype in 45 Streptococcus gallolyticus subsp. pasteurianus isolates
| Erythromycin phenotype | Clindamycin MIC (μg/mL) | Erythromycin MIC (μg/mL) | Erythromycin resistance genotype | Tetracycline MIC (μg/mL) | Tetracycline phenotype | Tetracycline resistance genotype | No. of isolates |
|---|---|---|---|---|---|---|---|
| cMLSB | > 1 | > 4 | > 8 | R | 2 | ||
| cMLSB | > 1 | > 4 | > 8 | R | 1 | ||
| cMLSB | > 1 | > 4 | > 8 | R | 1 | ||
| cMLSB | > 1 | > 4 | > 8 | R | 3 | ||
| cMLSB | > 1 | > 4 | 4 | I | Negative | 1 | |
| cMLSB | > 1 | > 4 | > 8 | R | 8 | ||
| cMLSB | > 1 | > 4 | > 8 | R | 1 | ||
| cMLSB | > 1 | > 4 | > 8 | R | 1 | ||
| cMLSB | > 1 | > 4 | > 8 | R | 1 | ||
| cMLSB | > 1 | > 4 | > 8 | R | 7 | ||
| cMLSB | > 1 | > 4 | > 8 | R | 5 | ||
| cMLSB | > 1 | > 4 | > 8 | R | 1 | ||
| cMLSB | > 1 | > 4 | > 8 | R | 1 | ||
| cMLSB | > 1 | > 4 | > 8 | R | 3 | ||
| cMLSB | > 1 | > 4 | > 8 | R | 1 | ||
| cMLSB | > 1 | > 4 | > 8 | R | 1 | ||
| cMLSB | > 1 | > 4 | > 8 | R | 1 | ||
| cMLSB | > 1 | > 4 | > 8 | R | 1 | ||
| S | 0.125 | ≤0.0625 | Negative | > 8 | R | 1 | |
| S | 0.0625 | ≤0.0625 | Negative | > 8 | R | 1 | |
| S | 0.0625 | ≤0.0625 | Negative | > 8 | R | 1 | |
| S | 0.0625 | ≤0.0625 | Negative | ≤0.5 | S | Negative | 2 |
cMLSB, constitutive macrolide-lincosamide-streptogramin B resistance; S/I/R: the isolates susceptible/intermediate/resistant to macrolide or tetracycline
Summary of the reported cases of clinical infections by Streptococcus gallolyticus subsp. pasteurianus
| present study | 1 [ | 2 [ | 3[ | 4 [ | 5[ | |
|---|---|---|---|---|---|---|
| Number | 45 | 20 patients (22 isolates were recovered) | 126 | 24 | 13 | 2 |
| Study period | 2011–2017 | May 2010-Jan 2012 | 2000–2012 | January 2003 and January 2010 | 2004–2010 | 1988–2014 |
| Country/area | China | Italy | Taiwan | Spain | Israel | Spain |
| Demographic characteristics | ||||||
| Gender (Male/female) | 17/28 | 7/13 | 79/47 | NA | 7/6 | 1/1 |
| Age (mean ± SD or median and IQD, years) | 67 ± 22 | 72 ± 13 | 70(55,78) | NA | 60 ± 33 | 89 and 62 |
| Age > 65 years | 19(42.2%) | 15 | 76(60%) | NA | NA | 1(50%) |
| Pregnant women | 11(24.4%) | 0 | NA | NA | 2(15%) | 0 |
| Neonates(< 3 months of age) | 1(2.2%) | 0 | NA | NA | 2(15%) | 0 |
| Paediatric patients (< 18 years) | 1(2.2%) | 0 | 5(4%) | NA | NA | NA |
| Infection types/source | Bacteremia (17), urine (16), bile (1), ascitic fluid (1), abdominal puncture fluid (1), peripancreatic drainage (1), peritoneal fluid (1), CSF(1) and fetal membrane/placenta (9) | UTI(10), bacteremia(2), limb ulcer (1), bile(3) | Bacteremia(126) | Bacteremia(24) | Bacteremia(13) | Spondylodiscitis/ paravertebral abscess (1), pubicsymphysitis and UTI(1) |
| Underlying diseases | ||||||
| Diabetes | 10(22.2%) | 8(40%) | 43(34%) | 2(8.3%) | 2(15%) | 1(50%) |
| Chronic renal failure | NA | 1(5%) | 22(17%) | 1(4.2%) | 3(23%) | NA |
| Liver disease | NA | 4(20%) | 53(42%) | NA | 4(31%) | NA |
| Malignancy (past or active) | 4(8.9%) | 6(30%) | 68(54%) | 9(37.5%, colonic adenoma (4); bladder cancer(1); prostate cancer(1); pulmonary cancer(1); mucosa-associated lymphoid tissue lymphoma (1); leukemia(1)) | 3(23%) | Adenoma(1); prostate cancer(1) |
| Gastrointestinal tract tumors | 4(8.9%) | 4(20%) | 51(40%, including colon/rectum, stomach, pancreas, liver, bile duct). | 4(16.7%) | 4(31%) | 1(50%) |
| Biliary pathology | 1(2.2%) | 4(20%) | 9(7%, biliary tract stone) | 5(20.8%) | 2(15%) | NA |
| Bacteriuria | 16(35.6%) | 14(70%)(50% UTI); | 2(2%) | 0 | NA | 1(50%) |
| Endocarditis | 1(2.2%) | 2(10%) | 17(13%) | 6(25%) | 3(23%) | 1(50%) |
| Identification methods | BD Phoenix 100, 16S rRNA/ | Phoenix100, 16S rDNA sequencing, MALDI Biotyper Bruker and Vitek MS | Vitek automated system; 16S rRNA and sodA genes and PCR-RFLP assays of groESL gene | API 20 Strep system, semiautomated Wider system, 16S rRNA and | PCR-RFLP/Vitek 2 | API 20 Strep system/ Vitek 2, 16S rRNA/ |
| Antibiotic susceptibility rate (median, μg/mL)(susceptibility rate(%)) | ||||||
| penicillin | 0.125(100) | NA(100) | 0.06(100) | NA (NA) | 0.06(100) | NA (NA) |
| cefatriaxone | < 0.5(100) | NA(100% to cefotaxime) | 0.12(100) | NA (NA) | 0.09(100) | NA (NA) |
| erythromycin | > 4(11.1%, | NA(68.2%, all resistant isolates belonged to the cMLSB phenotype, carried | 32(37%) | 0.5(62.5%) | NA (NA) | NA (NA) |
| clindamycin | > 4(11.1%) | NA(68.2%) | 0.06(39%) | 0.5(75%) | NA (NA) | NA (NA) |
| levofloxacin | 2(73.3%) | NA (NA) | 2(82%) | 0.5(91.7%) | NA (NA) | NA (NA) |
| vancomycin | ≤0.25 | NA (NA) | 0.5(100%) | NA (NA) | NA (NA) | NA (NA) |
| tetracycline (μg/mL) | > 8((4.4%), 39 strains carried | NA(31.8%, the resistant isolates carried | NA (NA) | NA (NA) | NA (NA) | NA (NA) |
NA Not available, CSF Cerebrospinal fluid, UTI urinary tract infection; Number in parentheses represents strains, and no number signified only one strain was detected